Impact of empiric antibiotics for methicillin-resistant (MRSA) infection and associated infection (CDI) risk: Secondary analysis of the CLEAR trial.

We performed secondary analyses of a postdischarge decolonization trial of MRSA carriers that reduced MRSA infection and hospitalization by 30%. Hospitalized MRSA infection was associated with 7.9 days of non-MRSA antibiotics and CDI in 3.